Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial

Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation.Read more

Cure3 2018: Art for Parkinson's

We are delighted that Cure3 is taking place again this year! Over 80 leading artists and architects will create exclusive works which will be sold at this unique selling exhibition...Read more

Parkinson’s Movement Awarded Wellcome Public Engagement Fund Grant

The Cure Parkinson's Trust (CPT) is delighted that Parkinson's Movement (PM) has secured a Wellcome Public Engagement Fund grant from The Wellcome Trust which will support the development of audio/visual content on the PM website over the next two years.Read more

Drug Repurposing in Parkinson's

Given the number of failures and the ever-increasing costs and lengthy processes for drug development, our attention continues to be focused on utilising existing compounds approved for other conditions as novel treatments for Parkinson’s...Read more

R S Macdonald Trust Awards Grant for Further Stem Cell Research

The Cure Parkinson’s Trust is delighted that the R S Macdonald Charitable Trust has awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath at the MRC in Edinburgh.Read more

Trial Design for Parkinson's Disease Modification

Helen Matthews, Deputy CEO, attended a recent summit in New York focused specifically on trial design for disease modification organised by The Michael J. Fox Foundation for Parkinson’s Research.Read more

Kyoto Team Begin Cell Replacement Trial In Parkinson's

Professor Jun Takahashi & colleagues at the University of Kyoto Japan have announced that they are to start the world’s first clinical trial of cells derived from induced pluripotent stem cells in people with Parkinsons...Read more

Cell Replacement Therapies for Parkinson's - Dr Tilo Kunath

Dr Tilo Kunath is working with cells derived from people with Parkinson's to understand the underlying causes of the condition; to test drugs that might treat it and to replace those cells which are lost.Read more

Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.Read more

LRRK2 May Play a Role in Idiopathic Parkinson's

Abnormally increased kinase activity due to mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is the cause of Parkinson’s in about 3 to 4% of people with Parkinson's however researchers have found that independent of any mutations, LRRK2 may also play a role in idiopathic Parkinson's.Read more

AMRC - Spotlight Report on Healthy Ageing

The AMRC's 'Spotlight Report on Healthy Ageing' is highlighting the work medical research charities are doing to prevent disease and promote health in the UK's ageing society...Read more

Peptron Announces Data of Sustained Release Exendin-4 for PD

Peptron has developed a novel form of the GLP-1 agonist SR-exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide in the brain...Read more

Herantis Announces Non-Invasive Treatment Plan of CDNF

Herantis Pharma has announced the initiation of a non-invasive CDNF development programme to broaden the application of CDNF in Parkinson's.Read more

The Lixisenatide Trial

Another trial in the promising GLP-1 cohort, this study will evaluate the effect of lixisenatide versus placebo on the progression of motor disability in people with early Parkinson's in order to assess its potential disease-modifying effect.Read more

The Liraglutide Trial

This GLP-1 receptor agonist study will test the efficacy and safety of liraglutide in the treatment of people with idiopathic Parkinson's (PD)...Read more

Astrocyte Conversion by Microglia is Neuroprotective in PD Models

Following the recent exenatide trial results, further studies of the potentially important disease-modifying role of GLP-1's in Parkinson's are taking place. This recent study further examines neuroprotection...Read more

The 100,000 Genomes Project and Parkinson's

The aim of this project is to create a new genomic medicine service for the NHS – transforming the way people are cared for. In time, there is the potential of new and more effective treatments. The project will also enable new medical research. Combining genomic sequence data with medical records is a ground-breaking resource...Read more

Hypertension Drug Shown to be Neuroprotective in Parkinson's

The calcium inhibitor drug Isradipine, which is usually used to treat high blood pressure, has shown neuroprotective effects in Parkinsons...Read more

The Belvoir Castle Charity Clay Shoot

The Cure Parkinson’s Trust (CPT) was delighted to have been chosen as one of the beneficiary charity’s for the annual Charity Clay Shoot, which took place at Belvoir Castle in Leicestershire, raising a fantastic £27,000 for CPT.Read more

Team 4Feet 4Paws 4Parkinson’s completes 200 mile walk round Scotland’s coastline

CPT's Lyndsey Isaacs, her black Labrador Indi and close friend Hanya Chlala have completed a 200 mile walk around the coast of Scotland. Naming their team ‘4Feet 4Paw’s 4Parkinson’s’, the trio took on this incredible two-week challenge in memory of Tom Isaacs. Here is Lyndsey's story...Read more

Type 2 Diabetes Linked to Higher Rate of Parkinson's

The study published in Neurology is the largest study to date on the link between the two conditions.Read more